Vince is an award-winning business lawyer, problem solver and dealmaker. His clients run the gamut from individual investors and entrepreneurs to widely held domestic and international corporations. Based in Portland, Oregon, he is Managing Partner of Harris Sliwoski and Editor of the Canna Law Blog and the Psychedelics Law Blog.
This is the second installment in my write-up of the proposed Oregon psilocybin program rules. I’m jumping in midstream from where I left off yesterday in Part 1. Similar to that installment, I will highlight the major areas, and skip or skim less prominent stuff. This batch of proposed rules is 65 pages, after all.
The Oregon Health Authority (OHA) released the rest of its draft psilocybin rules as predicted a few weeks back. We’ve had a minute to look at them. This post and the next few will cover some of the high points. In general, OHA did a good job implementing the Oregon Psilocybin Advisory Board’s (“Board”) recommendations
This will be one of the most important weeks for Oregon psilocybin to date, at least from a news and public information perspective. This is because we expect the Oregon Health Authority (OHA) to publish all remaining proposed administrative rules for the Oregon psilocybin program. The forthcoming rules should cover everything outlined in Measure 109
Welcome to the fifth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I will cover intellectual property considerations for Oregon psilocybin businesses. My law firm has written and presented many hundreds of times on intellectual property and controlled substances over the years. Mostly, this material focused on the
Friday was a great day for psychedelics. More generally, Friday was a great day for science and medicine, the rule of law and rational inquiry. This is because the DEA backed down on its clumsy attempt to ban five more psychedelic substances (tryptamines), which it had moved to place on Schedule I of the federal
In November 2020, Oregon voters passed Measure 109, which directs the Oregon Health Authority (OHA) to license and regulate the manufacture, delivery, sale, and administration of psilocybin. Licensing is set to kick off in early 2023. Things remain on track. We’ve written a lot about Measure 109 here on the Psychedelics Law Blog, including: 1)
Welcome to the fourth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I’ll cover access to professional service providers. Service Providers and the Oregon Psilocybin Industry I’ve mentioned before that Oregon psilocybin shares many parallels with what came before with cannabis. In the early days of cannabis, it
This article was originally published on Bill of Health, the blog of Petrie-Flom Center at Harvard Law School, as part of a digital symposium, A Macro View of Microdosing. In light of the widespread cultural and business culture adoption of microdosing, private sector employers should reconsider the implications of a blanket prohibition on workplace use of controlled substances. What
Measure 109 covered psilocybin testing standards in some detail. It also directed the Oregon Health Authority (OHA) to adopt rules on this topic. I’ll cover the unreleased, first draft of those rules today. They begin at OAR 333-333-7010. As I wrote in parts one and two of this series (training; products) it’s important to remember that
Oregon’s Measure 109 left much to do with “psilocybin products” to the administrative rulemaking process. Measure 109 defined “psilocybin products” as: “(A) psilocybin-producing fungi and (B) mixtures of substances containing a detectable amount of psilocybin.” Pretty simple. Beyond that, the measure directed the Oregon Health Authority to “establish a regulatory framework concerning psilocybin products.” This
